Pheochromocytoma crisis induced by glucocorticoids: A report of four cases and review of the literature

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Alejandro L. Rosas - , Houston Methodist Hospital (Autor:in)
  • Anna A. Kasperlik-Zaluska - , Medical Centre for Postgraduate Education, Warsaw (Autor:in)
  • Lucyna Papierska - , Medical Centre for Postgraduate Education, Warsaw (Autor:in)
  • Barbara Lee Bass - , Houston Methodist Hospital (Autor:in)
  • Karel Pacak - , National Institutes of Health (NIH) (Autor:in)
  • Graeme Eisenhofer - , Institut für Klinische Chemie und Laboratoriumsmedizin, Medizinische Klinik und Poliklinik III (Autor:in)

Abstract

Context: Pheochromocytoma crisis (PC) is a rare life-threatening endocrine emergency that may present spontaneously or can be unmasked by 'triggers', including certain medications that provoke the release of catecholamines by tumors. Several isolated cases of PC have been reported after administration of exogenous glucocorticoids; evidence that these drugs cause adverse events in patients with pheochromocytoma is mainly anecdotal. Patients: We report four cases of PC most likely induced by glucocorticoids and review seven previous reports in the literature linking steroid administration to the development of PC. Results: In four new cases reported here, glucocorticoid. administration was associated with a fatal outcome in one case, a pheochromocytoma multisystem crisis in another, and serious hypertensive crises in two others. Two patients had incidental adrenal masses and were undergoing high-dose dexamethasone suppression tests (DST). Conclusions: Exogenous glucocorticoids may unpredictably trigger PC. Pheochromocytoma. should be included in the differential diagnosis of any patient who develops a hypertensive crisis, cardiac failure, tachycardia, headache, and abdominal or chest pain after receiving exogenous glucocorticoids. Glucocorticoid induced PC is frequently associated with hemorrhagic pheochromocytoma. Although exogenous glucocorticoids cause serious complications unpredictably, they should be avoided or administered only if necessary and with caution in patients with known or suspected pheochromocytoma. During the investigation of incidental adrenal masses, pheochromocytoma should ideally be ruled out before administering glucocorticoids. However, no cases have been reported with 1 mg of dexamethasone when given as a DST in patients with pheochromocytoma; larger doses, as low as 2 mg of dexamethasone, may trigger a PC. A patient with pheochromocytoma presenting as an adrenal incidentaloma may also be at risk if exposed to glucocorticoids given as pre-treatment in case of allergy to contrast media.

Details

OriginalspracheEnglisch
Seiten (von - bis)423-429
Seitenumfang7
FachzeitschriftEuropean journal of endocrinology
Jahrgang158
Ausgabenummer3
PublikationsstatusVeröffentlicht - März 2008
Peer-Review-StatusJa

Externe IDs

PubMed 18299478

Schlagworte